- Home
- BRSP vs REPL Comparison
BRSP vs REPL Comparison
Compare BRSP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRSP
- REPL
- Stock Information
- Founded
- BRSP 2017
- REPL 2015
- Country
- BRSP United States
- REPL United States
- Employees
- BRSP N/A
- REPL N/A
- Industry
- BRSP Real Estate Investment Trusts
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- BRSP Real Estate
- REPL Health Care
- Exchange
- BRSP Nasdaq
- REPL Nasdaq
- Market Cap
- BRSP 730.1M
- REPL 780.3M
- IPO Year
- BRSP 2018
- REPL 2018
- Fundamental
- Price
- BRSP $5.71
- REPL $11.85
- Analyst Decision
- BRSP Hold
- REPL Strong Buy
- Analyst Count
- BRSP 5
- REPL 6
- Target Price
- BRSP $7.06
- REPL $17.50
- AVG Volume (30 Days)
- BRSP 631.6K
- REPL 818.5K
- Earning Date
- BRSP 02-19-2025
- REPL 02-06-2025
- Dividend Yield
- BRSP 11.28%
- REPL N/A
- EPS Growth
- BRSP N/A
- REPL N/A
- EPS
- BRSP N/A
- REPL N/A
- Revenue
- BRSP $378,095,000.00
- REPL N/A
- Revenue This Year
- BRSP N/A
- REPL N/A
- Revenue Next Year
- BRSP N/A
- REPL $300.41
- P/E Ratio
- BRSP N/A
- REPL N/A
- Revenue Growth
- BRSP N/A
- REPL N/A
- 52 Week Low
- BRSP $5.07
- REPL $4.92
- 52 Week High
- BRSP $7.71
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- BRSP 43.81
- REPL 51.79
- Support Level
- BRSP $5.40
- REPL $10.05
- Resistance Level
- BRSP $5.85
- REPL $11.20
- Average True Range (ATR)
- BRSP 0.15
- REPL 0.92
- MACD
- BRSP 0.01
- REPL -0.08
- Stochastic Oscillator
- BRSP 51.69
- REPL 51.97
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.